Home  »  Industry   »  Here are the top Institutional holders of Syros Ph...

Here are the top Institutional holders of Syros Pharmaceuticals Inc. (SYRS) shares

140 institutions hold shares in Syros Pharmaceuticals Inc. (SYRS), with 3.02M shares held by insiders accounting for 4.90% while institutional investors hold 89.79% of the company’s shares. The shares outstanding are 61.64M, and float is at 56.28M with Short Float at 9.62%. Institutions hold 85.38% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is ARK Investment Management, LLC with over 9.04 million shares valued at $98.1 million. The investor’s holdings represent 14.67% of the SYRS Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 6.64 million shares valued at $72.05 million to account for 10.77% of the shares outstanding. The other top investors are Bain Capital Life Sciences Investors, LLC which holds 5.79 million shares representing 9.39% and valued at over $62.77 million, while Nikko Asset Management Americas, Inc. holds 7.11% of the shares totaling 4.38 million with a market value of $47.54 million.

Syros Pharmaceuticals Inc. (NASDAQ: SYRS) is -38.62% lower on its value in year-to-date trading and has touched a low of $5.75 and a high of $15.65 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The SYRS stock was last observed hovering at around $6.54 in the last trading session, with the day’s gains setting it 0.12% off its average median price target of $16.00 for the next 12 months. It is also 66.7% off the consensus price target high of $20.00 offered by 8 analysts, but current levels are 48.77% higher than the price target low of $13.00 for the same period.

Currently trading at $6.66, the stock is -1.76% and -20.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.83 million and changing 1.83% at the moment leaves the stock -33.12% off its SMA200. SYRS registered -17.88% loss for a year compared to 6-month gain of -10.24%. The firm has a 50-day simple moving average (SMA 50) of $7.60 and a 200-day simple moving average (SMA200) of $9.40.

The stock witnessed a -18.98% loss in the last 1 month and extending the period to 3 months gives it a -45.50%, and is 13.46% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.17% over the week and 7.59% over the month.

Syros Pharmaceuticals Inc. (SYRS) has around 103 employees, a market worth around $399.20M and $15.10M in sales. Distance from 52-week low is 15.83% and -57.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-62.90%).

Syros Pharmaceuticals Inc. (SYRS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Syros Pharmaceuticals Inc. (SYRS) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.90, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Syros Pharmaceuticals Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.46 with sales reaching $2.67M over the same period.The EPS is expected to grow by 2.70% this year, but quarterly earnings will post -18.90% year-over-year.

Syros Pharmaceuticals Inc. (SYRS) Insider Activity

A total of 12 insider transactions have happened at Syros Pharmaceuticals Inc. (SYRS) in the last six months, with sales accounting for 7 and purchases happening 5 times. The most recent transaction is an insider sale by Olson Eric R, the company’s Chief Scientific Officer. SEC filings show that Olson Eric R sold 3,628 shares of the company’s common stock on Mar 15 at a price of $9.47 per share for a total of $34372.0. Following the sale, the insider now owns 0.0 shares.

Syros Pharmaceuticals Inc. disclosed in a document filed with the SEC on Feb 16 that Young Richard A (Director) sold a total of 3,750 shares of the company’s common stock. The trade occurred on Feb 16 and was made at $12.05 per share for $45188.0. Following the transaction, the insider now directly holds 0.32 million shares of the SYRS stock.

Still, SEC filings show that on Feb 08, Young Richard A (Director) disposed off 3,750 shares at an average price of $13.04 for $48900.0. The insider now directly holds 325,461 shares of Syros Pharmaceuticals Inc. (SYRS).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Syros Pharmaceuticals Inc. (SYRS): Who are the competitors?

The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -14.79% down over the past 12 months. Short interest in the company’s stock has fallen -34.24% from the last report on Mar 30, 2021 to stand at a total of 5.41 million short shares sold with a short interest ratio of 6.8.

Related Posts

How does pre market trading work?

In pre-market trading, trades are made before the main market session opens. Pre-market trading is typically done between 8:00 a.m. and 9:30 a.m. EST. Market

Hot Penny Stocks to Watch Today

The Covid-19 pandemic has made the biggest impact on blue chips and under $1 stocks (penny stocks), as is typical of the general business environment.




Download Free eBook For

100% free. stop anytime no spam